Hims & Hers Health, Inc. (NYSE:HIMS) Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. grew its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 164.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 51,577 shares of the company's stock after purchasing an additional 32,108 shares during the period. Victory Capital Management Inc.'s holdings in Hims & Hers Health were worth $950,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. CWM LLC lifted its holdings in Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company's stock valued at $110,000 after buying an additional 1,054 shares during the period. Arizona State Retirement System increased its stake in Hims & Hers Health by 3.0% in the 2nd quarter. Arizona State Retirement System now owns 40,344 shares of the company's stock valued at $815,000 after buying an additional 1,173 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company's stock worth $37,000 after acquiring an additional 1,603 shares during the period. Amalgamated Bank grew its position in Hims & Hers Health by 55.9% during the second quarter. Amalgamated Bank now owns 6,566 shares of the company's stock valued at $133,000 after buying an additional 2,354 shares during the period. Finally, nVerses Capital LLC grew its position in shares of Hims & Hers Health by 31.8% during the 3rd quarter. nVerses Capital LLC now owns 14,100 shares of the company's stock valued at $260,000 after acquiring an additional 3,400 shares during the period. Institutional investors and hedge funds own 63.52% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. TD Cowen reaffirmed a "buy" rating and issued a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a research report on Wednesday, November 6th. Canaccord Genuity Group lifted their price target on Hims & Hers Health from $24.00 to $28.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. Piper Sandler reiterated a "neutral" rating and issued a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Finally, Bank of America lowered Hims & Hers Health from a "buy" rating to an "underperform" rating and dropped their price objective for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $20.71.

Insider Buying and Selling

In other news, CFO Oluyemi Okupe sold 101,993 shares of the company's stock in a transaction on Monday, November 25th. The shares were sold at an average price of $29.62, for a total transaction of $3,021,032.66. Following the transaction, the chief financial officer now directly owns 109,392 shares of the company's stock, valued at $3,240,191.04. This represents a 48.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the firm's stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total value of $2,750,209.28. Following the completion of the transaction, the chief executive officer now directly owns 33,502 shares of the company's stock, valued at $487,789.12. The trade was a 84.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,153,519 shares of company stock worth $24,486,721 over the last 90 days. 17.71% of the stock is owned by insiders.

Hims & Hers Health Stock Performance

Shares of HIMS stock traded down $0.34 on Thursday, reaching $30.34. 24,738,795 shares of the company were exchanged, compared to its average volume of 9,806,751. The business has a 50-day moving average price of $21.14 and a 200 day moving average price of $19.57. The company has a market cap of $6.63 billion, a price-to-earnings ratio of 68.98 and a beta of 1.06. Hims & Hers Health, Inc. has a 1 year low of $8.09 and a 1 year high of $35.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm's revenue for the quarter was up 77.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.04) earnings per share. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.